Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

FDA PMA

Transcervical contraceptive tubal occlusion device

PMA Number: P020014 · 2018-04-09

ApplicantBayer Pharma AG
Decision Date2018-04-09
PMA NumberP020014
Product CodeHHS
Device ClassClass 3
Medical SpecialtyO
Regulation Number21 CFR 8
Advisory CommitteeOB

Device Summary

Transcervical contraceptive tubal occlusion device is the device name listed in this FDA 510(k) record. The listed applicant is Bayer Pharma AG. It received FDA 510(k) clearance on 2018-04-09. The device is classified under product code HHS. It was reviewed by the OB advisory panel.

Frequently Asked Questions

What is the Transcervical contraceptive tubal occlusion device?

Transcervical contraceptive tubal occlusion device is a medical device that received FDA 510(k) clearance on 2018-04-09. The listed applicant is Bayer Pharma AG.

When did Transcervical contraceptive tubal occlusion device receive FDA 510(k) clearance?

The clearance date for Transcervical contraceptive tubal occlusion device can be found in the official FDA records.

Who is the listed applicant for Transcervical contraceptive tubal occlusion device?

The FDA 510(k) record lists Bayer Pharma AG as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for Transcervical contraceptive tubal occlusion device?

The FDA product code for Transcervical contraceptive tubal occlusion device is HHS.

Related Clinical Trials

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

NCT07608549FLASH Pilot Phase 1 Safety StudyNOT_YET_RECRUITINGNCT06562205PAP Systems External Clinical Studies (ECS)NOT_YET_RECRUITINGNCT04745156A Study Using Brain Stimulation and Behavioral Therapy to Increase Extent of Resection in Low-Grade GliomasNOT_YET_RECRUITINGNCT06443177The Effect of Sympathetic Modulation on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid HemorrhageSUSPENDED

Official Source

View on FDA Database →

Data sourced from FDA Open API. For the most current and authoritative information, always refer to the official record.

↑